Tsar & Tsai represented Marubeni Corporation in obtaining merger clearance from the Taiwan Fair Trade Commission for its acquisition of a 60% stake (approximately JPY 45 billion) in the newly established Marubeni Pharmaceuticals Corporation. The new company will take over Sumitomo Pharma Co., Ltd.’s pharmaceutical sales business in Asia through a simplified absorption-type company split.

Our team successfully secured a simplified review procedure and obtained unconditional clearance in a shorter time than the average review period (which is generally around six to eight weeks). This successful filing was led by Partner Matt Liu, Integrated Partner Yichu Chen, and Associate Ariel Liu.